Scientists designed B7-H3-specific CAR T cells, confirmed their preclinical efficacy, and opened BrainChild-03, a first-in-human Phase I trial employing repeated locoregional B7-H3CARs to children with recurrent/refractory central nervous system tumors and diffuse intrinsic pontine glioma.
[Cancer Discovery]